¥5,889.00
1.32%
Tokyo, Sep 24, 03:12 pm JST. Closed.
ISIN
JP3463000004
Symbol
4502
Index

Takeda Pharmaceutical Target price 2026 - Analyst rating & recommendation

Takeda Pharmaceutical Classifications & Recommendation

Buy
67%
Hold
33%

Takeda Pharmaceutical Price Target

Target Price ¥6,834.00
Price ¥5,885.00
Potential
Number of Estimates 18
18 Analysts have issued a price target Takeda Pharmaceutical 2027 . The average Takeda Pharmaceutical target price is ¥6,834.00. This is higher than the current stock price. The highest price target is
¥7,980.00 35.60%
register free of charge
, the lowest is
¥5,454.00 7.32%
register free of charge
.
A rating was issued by 21 analysts: 14 Analysts recommend Takeda Pharmaceutical to buy, 7 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Takeda Pharmaceutical stock has an average upside potential 2027 of . Most analysts recommend the Takeda Pharmaceutical stock at Purchase.

Sales and Margin forecast 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Revenue Billion ¥ 4,505.72 4,747.12
1.66% 5.36%
EBITDA Margin 25.82% 25.55%
6.82% 1.06%
Net Margin -3.38% 4.42%
243.57% 230.69%

18 Analysts have issued a sales forecast Takeda Pharmaceutical 2027 . The average Takeda Pharmaceutical sales estimate is

¥4.7t
unlock
. This is
2.78% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
¥5.1t 9.84%
unlock
, the lowest is
¥4.5t 1.91%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 ¥4.5t 1.66%
2027
¥4.7t 5.36%
unlock
2028
¥4.8t 1.72%
unlock
2029
¥5.0t 2.81%
unlock

15 Analysts have issued an Takeda Pharmaceutical EBITDA forecast 2027. The average Takeda Pharmaceutical EBITDA estimate is

¥1.2t
unlock
. This is
90.71% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
¥1.5t 135.88%
unlock
, the lowest is
¥1.0t 64.16%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2026 ¥1.2t 5.05%
2027
¥1.2t 4.22%
unlock
2028
¥1.3t 9.65%
unlock
2029
¥1.4t 5.18%
unlock

EBITDA Margin

2026 25.82% 6.82%
2027
25.55% 1.06%
unlock
2028
27.54% 7.79%
unlock
2029
28.17% 2.29%
unlock

19 Takeda Pharmaceutical Analysts have issued a net profit forecast 2027. The average Takeda Pharmaceutical net profit estimate is

¥210b
unlock
. This is
228.41% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
¥302b 284.78%
unlock
, the lowest is
¥158b 196.94%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 ¥-152b 241.20%
2027
¥210b 237.72%
unlock
2028
¥352b 67.84%
unlock
2029
¥426b 20.80%
unlock

Net Margin

2026 -3.38% 243.57%
2027
4.42% 230.69%
unlock
2028
7.29% 64.93%
unlock
2029
8.57% 17.56%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Earnings Per Share ¥ -96.75 132.80
241.53% 237.26%
P/E 44.94
EV/Sales 2.94

19 Analysts have issued a Takeda Pharmaceutical forecast for earnings per share. The average Takeda Pharmaceutical EPS is

¥132.80
unlock
. This is
228.38% higher
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
¥191.10 284.74%
unlock
, the lowest is
¥100.25 196.92%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 ¥-96.75 241.53%
2027
¥132.80 237.26%
unlock
2028
¥222.90 67.85%
unlock
2029
¥269.26 20.80%
unlock

P/E ratio

Current -57.70 212.74%
2027
44.94 177.89%
unlock
2028
26.77 40.43%
unlock
2029
22.16 17.22%
unlock

Based on analysts' sales estimates for 2027, the Takeda Pharmaceutical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.02 21.29%
2027
2.94 2.78%
unlock
2028
2.89 1.69%
unlock
2029
2.81 2.74%
unlock

P/S ratio

Current 2.06 31.00%
2027
2.01 2.70%
unlock
2028
1.97 1.69%
unlock
2029
1.92 2.74%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today